Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.
Alterity Therapeutics announced its participation in the 2025 International MSA Congress, where it will present multiple oral and poster presentations on its clinical programs for Multiple System Atrophy (MSA). The presentations will highlight the Phase 2 data for ATH434, which has shown significant clinical efficacy and safety in treating MSA. The company’s involvement in the congress underscores its commitment to advancing MSA research and care, further supported by the recent Fast Track Designation for ATH434 by the US FDA.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Their primary product, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins, with potential applications in treating Parkinson’s disease and Multiple System Atrophy (MSA).
Average Trading Volume: 19,021,566
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$82.15M
Learn more about ATH stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue